# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical val...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow tr...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market openin...
Subject to Biodesix stockholder approval, each share of Series A Non-Voting Convertible Preferred Stock will automatically conv...
Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercial...
Canaccord Genuity analyst Kyle Mikson reiterates Biodesix (NASDAQ:BDSX) with a Buy and maintains $3.5 price target.